Co-delivery of IOX1 and doxorubicin for antibody-independent cancer chemo-immunotherapy - Liu, Jing; Zhao, Zhihao; Qiu, Nasha; Zhou, Quan; Wang, Guowei; Jiang, Haiping; Piao, Ying; Zhou, Zhuxian; Tang, Jianbin; Shen, Youqing (Nature communications, 2021)
Keywords: 13/109; 13/2; 13/21; 13/31; 14; 14/1; 14/19; 14/63; 38/88; 38/90; 59/5; 631/67/1059/2325; 631/67/1059/99; 631/67/1504/1885; 631/67/322; 631/67/580; 64/60; 8-Hydroxyquinoline; 82/80; Animals; Antibodies; Antibodies - immunology; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Apoptosis; B7-H1 Antigen - antagonists & inhibitors; B7-H1 Antigen - immunology; B7-H1 Antigen - metabolism; Cancer; Cell death; Cell Line, Tumor; Cell Survival - drug effects; Cell Survival - immunology; Chemotherapy; Doxorubicin; Doxorubicin - administration & dosage; Doxorubicin - pharmacology; Glycoproteins; HCT116 Cells; Histones; Humanities and Social Sciences; Humans; Hydroxyquinoline; Hydroxyquinolines - administration & dosage; Hydroxyquinolines - chemistry; Hydroxyquinolines - pharmacology; Immune checkpoint; Immunogenicity; Immunological memory; Immunology; Immunosuppressive agents; Immunotherapy; Immunotherapy - methods; Infiltration; Inhibitors; Lung cancer; Lymphocytes; Lymphocytes T; MCF-7 Cells; Metastases; Mice; Mice, Inbred BALB C; Mice, Nude; Mortality; multidisciplinary; Neoplasms - immunology; Neoplasms - metabolism; Neoplasms - therapy; Neoplasms, Experimental - immunology; Neoplasms, Experimental - metabolism; Neoplasms, Experimental - therapy; NIH 3T3 Cells; PD-1 protein; PD-L1 protein; Programmed Cell Death 1 Receptor - antagonists & inhibitors; Programmed Cell Death 1 Receptor - immunology; Programmed Cell Death 1 Receptor - metabolism; Science; Science (multidisciplinary); T-Lymphocytes - drug effects; T-Lymphocytes - immunology; T-Lymphocytes - metabolism; Tumor Burden - drug effects; Tumor Burden - immunology; Tumors; β-Catenin